A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Trial Profile

A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Olaparib (Primary) ; Onalespib (Primary)
  • Indications Adenocarcinoma; Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Jun 2017 Planned End Date changed from 31 Oct 2019 to 1 Jun 2020.
    • 15 Jun 2017 Planned primary completion date changed from 31 Oct 2019 to 1 Jun 2020.
    • 15 Jun 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top